Mylan Specialty L.P.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$8.5Mgeneral payments (2019-2025)
$138Kresearch payments (2019-2025)
33,149clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Mark Pamer | Port Saint Lucie, FL | Pulmonary Disease | $186,651.01 |
| Antonio Anzueto | San Antonio, TX | Pulmonary Disease | $180,891.65 |
| William Alleyne | Rock Hill, SC | Critical Care Medicine (Internal Medicine) | $109,857.95 |
| Aaron Milstone | Franklin, TN | Pulmonary Disease | $96,562.47 |
| William Mckenzie | Panama City, FL | Pulmonary Disease | $95,226.12 |
| Tarun Madappa | Corpus Christi, TX | Pulmonary Disease | $92,406.41 |
| Asaad Jandali | Munster, IN | Pulmonary Disease | $91,531.07 |
| Fariborz Rezai | Livingston, NJ | Critical Care Medicine (Internal Medicine) | $88,974.85 |
| Israel Rubinstein | Chicago, IL | Critical Care Medicine (Internal Medicine) | $82,034.89 |
| Abhijit Raval | Anderson, SC | Pulmonary Disease | $78,521.27 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.